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Abstract
Background: The important role of network meta-analysis of randomized clinical trials in health technology assessment
and guideline development is increasingly recognized. This approach has the potential to obtain conclusive results earlier
than with new standalone trials or conventional, pairwise meta-analyses.
Methods: Network meta-analyses can also be used to plan future trials. We introduce a four-step framework that aims
to identify the optimal design for a new trial that will update the existing evidence while minimizing the required
sample size. The new trial designed within this framework does not need to include all competing interventions and
comparisons of interest and can contribute direct and indirect evidence to the updated network meta-analysis. We
present the method by virtually planning a new trial to compare biologics in rheumatoid arthritis and a new trial to
compare two drugs for relapsing-remitting multiple sclerosis.
Results: A trial design based on updating the evidence from a network meta-analysis of relevant previous trials may
require a considerably smaller sample size to reach the same conclusion compared with a trial designed and analyzed
in isolation. Challenges of the approach include the complexity of the methodology and the need for a coherent
network meta-analysis of previous trials with little heterogeneity.
Conclusions: When used judiciously, conditional trial design could significantly reduce the required resources for a
new study and prevent experimentation with an unnecessarily large number of participants.
Keywords: Sample size, Conditional power, Evidence synthesis, Rheumatoid arthritis, Historical data
Background
The role of evidence synthesis in directing future research,
in general, and planning clinical trials, in particular, has
been debated widely in the medical and statistical litera-
ture [1, 2]. Researchers designing new studies possibly
consult other relevant studies informally to inform their
assumptions about the anticipated treatment effect, vari-
ability in the health outcome, or response rate. Empirical
evidence has shown, however, that most randomized
controlled trials (RCTs) do not consider systematic
reviews or meta-analyses to inform their design [3–7].
One potential reason is that the available conventional
meta-analyses addressed only a subset of the treatment
comparisons of interest that were being considered for the
new trial. It is possible that the treatment comparison of
interest has not been examined before and consequently
there is no prior direct evidence to inform the future trial.
However, the treatments of interest might have been
compared to a common reference treatment in previous
studies yielding indirect evidence about the comparison of
interest.
In recent years, methods to synthesize evidence across
trials of multiple comparisons, called network
meta-analysis (NMA), have become more widely used [8].
In NMAs, direct evidence from trials comparing treat-
ments of interest (for example, treatments A and B) and
indirect evidence from trials comparing the treatments of
interest with a common comparator (for example, A and
C, and B and C) is synthesized. Methods to plan a clinical
trial specifically to update a pairwise meta-analysis were
proposed ten years ago [9–11] and recently have been
extended to the setting of NMAs [12, 13].
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For example, in 2015, a NMA based on 26 trials
showed that percutaneous coronary intervention with
everolimus-eluting stents (EES) is more effective in the
treatment of in-stent restenosis than the widely used
intervention with drug-coated balloons, based on direct
and indirect evidence [14]. Even in 2013, evidence from
19 trials favored EES but the estimate was imprecise
with wide confidence intervals and entirely based on in-
direct comparisons. Two additional trials of drug-eluting
balloons versus EES were subsequently published, which
included 489 patients with in-stent restenosis (see
Additional file 1). The inclusion of these two trials in the
NMA rendered the evidence for the superiority of EES
conclusive. The two studies were planned independently
of each other and without taking the existing indirect
evidence into account. In fact, a single study with 232
patients would have sufficed to render the estimate from
the NMA conclusive. In other words, the evidence could
have become available earlier, with fewer patients being
exposed to an inferior treatment.
In this article, we illustrate how future trials evaluating
the efficacy or safety of interventions can be planned
based on updating NMA of previous trials, using an
approach we call conditional trial design. Conditional trial
design aims to identify the optimal new trial conditional
on the existing network of trials to best serve timely
clinical and public health decision-making. Based on
recent methodological work from our group and others,
we discuss advantages and disadvantages of the approach.
Methods
We first describe the conditional trial design and then we
discuss important challenges that are likely to be encoun-
tered in application.
Conditional trial design
The approach is a step-wise process outlined below.
Identify or perform a coherent network meta-analysis that
addresses your research question
The starting point is a NMA about the relative efficacy or
safety of competing interventions for the same health
condition. The NMA should be the result of a methodo-
logically robust systematic review that aims to reduce the
risk of publication and other bias. We also assume that
between-study heterogeneity is low to moderate and the
assumption of coherence is justified. In other words, for
each treatment comparison the results across the different
studies are reasonably similar (low heterogeneity, Table 1)
and direct and indirect evidence are in agreement (coher-
ence). Evaluation of homogeneity and coherence in a
network can be performed using appropriate statistical
quantities and tests and by comparing the characteristics
of the studies (Additional file 1).
Define the targeted comparison or comparisons between
the treatments of interest whose relative effects you want
to measure
In a next step the comparison or comparisons of interest,
i.e. the “targeted comparisons” need to be defined. Of note,
NMAs typically include comparisons with placebo or with
older treatments that are not of interest per se, but may
provide indirect evidence on the targeted comparisons.
Depending on the clinical context the process of defining
the targeted comparisons may be complex, involve many
stakeholders, and might result in several targeted treatment
comparisons.
Decide whether the network meta-analysis answers the
research question
For each targeted comparison we need to establish whether
the available evidence from the NMA is conclusive or not,
and if not, that a further trial or trials are indeed warranted.
An estimate of a relative effect might be characterized as
inconclusive if the confidence interval around it is wide and
includes both a worthwhile beneficial and harmful effect
and generally includes values that could lead to different
Table 1 A suggested strategy for measuring and addressing
heterogeneity when planning a future study to update a
network meta-analysis
1. Measure and characterize heterogeneity. Latest methodological
developments encourage meta-analysts to estimate the heterogeneity
variance which measures the variability of the true treatment effect and
compare it to its expected value. Within the context of planning new
studies, existing heterogeneity is large when even a new study with
several thousands of participants fails to produce effect sizes that are
precise enough to enable decision-making. Consequently, characterizing
heterogeneity as large or small depends on the context. We recommend
that when the heterogeneity variance is below the expected, sample size
calculations are carried out; if the estimated sample size is unrealistically
large, then heterogeneity is clearly too large to proceed with conditional
trial design.
2. Understand heterogeneity. Identify potential effect modifiers and
explore the changes of the treatment effect in various subgroup analyses
using study-level and patient-level characteristics (such as risk of bias,
trial setting). The impact of continuous characteristics (such as trial
duration or sample size) can be explored using meta-regression models.
Interpret with caution any findings from patient-level covariates as they
can be subject to ecological bias.
3. Reduce heterogeneity. If some variables are associated with
heterogeneity, then consider the treatment effects about a particular
group of patients and trial settings. For example, investigators might
choose to restrict the analysis in low risk of bias or recent studies or
estimate the treatment effect for a very large study (from a meta-
regression on sample size). Any post hoc decisions about the analyzed
dataset need to be clearly documented to avoid selection bias.
4. What to do in the presence of large, unexplained heterogeneity. If
the heterogeneity remains substantial even after efforts to pinpoint its
source and reduce it, then investigators have the following options: (1)
collect individual-patient data to better investigate the role of patient
characteristics in modifying the treatment effect and go to step 2
above; (2) develop assumptions about what is possibly causing the
heterogeneity and plan a new exploratory study to investigate these
assumptions. For example, if investigators believe that treatment dose
is associated with differential effects (and this information is scarcely
reported in the included studies) a new multi-arm study can be planned
to investigate this assumption.
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clinical decisions. When the hierarchy of treatment effect-
iveness is of interest, we consider the available evidence as
inconclusive if the ranking of the treatments is imprecise,
i.e. the probabilities of a treatment of being best or worst
are similar.
Estimate the features of a future study that will update the
network to answer the research question
Once it is clear that additional evidence is required, we
can proceed to planning the next trial. The new trial could
compare the treatments in the targeted comparison or
other treatments included in the network (“tested
comparison”). In this case, the trial will contribute indirect
evidence to the targeted comparison via the updated
network. The choice of the targeted comparison depends
on the research priorities in the clinical field and the
values of the stakeholders involved in planning the
research agenda. In contrast, decisions about the compari-
son actually tested in the new trial involve primarily prac-
tical considerations related to the feasibility of the trial
(e.g. recruitment rate with the various treatment options)
and sample size. In this article, we focus on the sample
size criterion; we would choose to test the comparison
which minimizes the required sample size, typically that is
the targeted comparison.
We have previously proposed a statistical methodology
to estimate the sample size for a new trial within a condi-
tional framework that takes the available evidence into
account (Additional file 1). This methodology has two var-
iants. The first one is based on the classical
hypothesis-testing concept. The sample size is estimated
as a function of the conditional power; that is the power
of the updated NMA when a new study is added and uses
extensions of classical power calculations [12]. The second
variant is based on estimating treatment effects rather
than testing. The sample size is calculated to improve the
precision of the estimate from the updated NMA so that
clinically important effects can either be confirmed or ex-
cluded [13]. For both approaches the required sample size
will be lower for a conditionally designed trial compared
to a trial designed and analyzed in isolation. The two
methods are essentially equivalent, but practical consider-
ations may lead to a preference of one over the other. For
example, if the ranking of several treatments is of interest,
then the targeted comparisons are all comparisons be-
tween them and sample size calculations are more easily
done using the second variant.
If the tested comparison is not the same as the targeted
comparison the study will improve the precision in the
estimates of the targeted comparison by contributing to
its indirect evidence, but it will require a larger sample size
to achieve the same level of precision or power compared
to a study of the targeted comparison. Indirect evidence
may be preferable in some situations, for example if one
of the treatments of interest is more invasive or more
inconvenient than the comparator of interest. Careful
inspection of the existing network graph is important if
the new trial is to provide indirect evidence: links between
the treatments tested and the treatments of interest are
required. Note that equipoise between the tested treat-
ments will always need to be documented.
Limitations of the conditional planning framework
A number of factors will limit the pragmatic applicability
of the conditional planning framework. For instance, it
will be irrelevant to the planning of a trial to evaluate a
new intervention or when the primary outcome of inter-
est has not been considered in previous trials. NMA
rests on the assumption of coherence and only under
this condition can be considered as the basis for trial
design. However, evaluation of the assumption is
challenging in practice (see Additional file 1), particu-
larly for poorly connected networks with few studies.
We have also stressed that between-study heterogeneity
should be low for the total network and the targeted
comparison in particular. If heterogeneity is large, the
contribution of a single study, even if the study is large,
is low and the precision of the treatment effect esti-
mated by the NMA remains low [9, 10, 12]. Indeed, het-
erogeneity sets an upper bound to the precision of the
summary effect beyond which precision cannot be im-
proved: the upper bound of the attainable precision is
equal to the number of studies divided by the heterogen-
eity variance (see formula in Additional file 1). Addition-
ally, as heterogeneity increases, interpretation of the
synthesis becomes more problematic.
Estimation of heterogeneity requires several studies to
be available for the targeted comparison. In the absence
of many direct studies, the common heterogeneity esti-
mated from the network can be considered along with
empirical evidence, specific to the outcome and treat-
ment comparison (Table 1). If there are is substantial
heterogeneity it will not be possible to design a single
trial based on the conditional trial design approach. If
heterogeneity is large, and the sources of heterogeneity
are well understood, planning several smaller studies
instead, for example in patients with different character-
istics, may be a more powerful approach than planning a
single large trial in one patient group (Table 1).
Results
We considered two examples from the published literature.
We first consider the case of biologic and conventional
disease-modifying anti-rheumatic drugs (DMARDs) for
rheumatoid arthritis (RA). A second example, of treatments
for multiple sclerosis (MS), is also presented.
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Treatments for rheumatoid arthritis
Methotrexate is the “anchor drug” for RA and recom-
mended as the first DMARD. It is unclear, however,
whether a biologic DMARD should be added to the initial
therapy or whether initial therapy should be based on the
less costly triple therapy of conventional DMARDS, i.e.
methotrexate plus sulfasalazine plus hydroxychloroquine.
A recent NMA of RCTs in methotrexate-naïve patients
concluded that triple therapy and regimens combining
biologic DMARDs with methotrexate were similarly ef-
fective in controlling disease activity (Fig. 1) [15]. Hetero-
geneity was low to moderate; the between-study variance
was τ2 = 0.03. The assumption of coherence was deemed
plausible after considering trial characteristics, although
the lack of direct evidence for many comparisons does not
allow formal statistical evaluation.
Methothrexate combined with etanercept was associated
with higher average response (defined as the American
College of Rheumatology [ACR] 50 response) compared to
all other treatments in the network. Synthesis of evidence
from the one direct trial (with 376 patients [16]) with
indirect evidence in the network favored methotrexate plus
etanercept over the triple therapy in terms of efficacy but
with considerable uncertainty: the odds of response were
lower with triple therapy (odds ratio [OR] = 0.71) but the
95% confidence interval was wide (0.42–1.21). Clearly, the
available evidence on the targeted comparison is inconclu-
sive. A more precise estimate of the comparative efficacy of
the two therapies would add clarity to whether any added
benefit of etanercept justifies the extra cost and thus would
be of interest to guideline developers and reimbursement
agencies.
A trial directly comparing methotrexate plus etanercept
and triple therapy is the most efficient approach to gener-
ating the required additional evidence. Figure 2 shows the
gain in power for a new etanercept and methotrexate
versus triple conventional DMARD therapy trial when
designed conditional on the existing network of trials.
Assuming equal arm allocation at randomization, a trial
with 280 patients in total will enable the updated NMA to
detect an OR of 0.71 with 80% power. The corresponding
sample sizes for a conventional pairwise meta-analysis
(pooling with the existing study [16]) or a standalone trial
are 790 and 1084 patients, respectively.
Additional file 1 presents technical guidance to allow
inclined readers to re-produce results.
Treatments for relapsing-remitting multiple sclerosis
In 2015, the association of British Neurologists published
guidelines about choosing treatments for MS [17]. The
guidelines classify fingolimod, dimethyl fumarate,
beta-interferon, and glatiramer acetate in the category of
Fig. 1 Network of evidence of treatments for rheumatoid arthritis. Adapted from Hazlewood et al. [15]. ABAT abatacept, ADA adalimumab,
AZA azathioprine, CQ chloroquine, ETN etanercept, Ctl certolizumab, CyA cyclosporin, GOL golimumab, HCQ hydroxychloroquine, IFX infliximab,
IM intramuscular, IR inadequate response, iv intravenous, LEF leflunomide, MTX methotrexate, RTX rituximab, sc subcutaneous, SSZ sulfasalazine,
TOFA tofacitinib, TCZ tocilizumab, triple methotrexate plus sulfasalazine and hydroxychloroquine
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moderate efficacy. They recommend that patients with
relapsing-remitting condition start with fingolimod or
dimethyl fumarate because they are most effective and are
administered orally.
A relevant NMA with low heterogeneity (τ2 = 0.01) and
no serious concerns about incoherence was published in
the same year (Fig. 3) [18]. The results, while broadly in
line with Scolding et al. [17], show some differences
between the drugs in the moderate efficacy group. Fin-
golimod is shown to considerably decrease the rate of
relapses compared to dimethyl fumarate, while evi-
dence is weak to support the advantage of fingolimod
over glatiramer acetate (risk ratio [RR] = 0.88
[0.74–1.04]). As reported in the guidelines, glatiramer
acetate has been used “extensively for decades in MS”
and its safety profile is well understood, in contrast to
fingolimod, which is a newer agent (only two
placebo-controlled trials were included in the review).
Patients, their doctors, and guideline developers might
want stronger evidence against the similar efficacy of
these two interventions.
We estimated the sample size required in a new trial
that compares fingolimod and glatiramer acetate to up-
date the network using the precision-minimization
approach. Assuming a 51% relapse rate for glatiramer
acetate, 552 participants are needed in a fingolimod
versus glatiramer acetate study to update the NMA and
exclude a RR of 1 in the fingolimod versus glatiramer
acetate RR. An independently designed and analyzed
study would need 1200 participants to achieve the same
level of precision. Note that the targeted comparison
does not have direct evidence and fingolimod is con-
nected only to placebo; consequently, precision can be
improved only if fingolimod is included in the new
study. A fingolimod versus dimethyl fumarate study
would need a much larger sample size to achieve the
same level of precision in the fingolimod vs glatiramer
acetate updated RR (2742 participants).
Fig. 2 Power and conditional power to detect a difference in response
between triple therapy vs methotrexate combined with etanercept as a
function of the sample size. The difference anticipated in a new study
was of OR = 0.71 in American College of Rheumatology (ACR) 50
response favoring methothrexate/etanercept. Power for a single
randomized trial considered in isolation (dotted line), conditional power
for a fixed effect pairwise meta-analysis (dashed line, two studies), and
network meta-analysis (solid line). Expected event rate in the triple therapy
was assumed equal to the average observed in the network (49%).
Calculations were performed using the conditional power method [12]
Fig. 3 Network of evidence of treatments for multiple sclerosis. Adapted from Tramacere et al. [18]
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Discussion
We present a framework of conditional trial design that has
the potential to reduce the resources needed to answer a
clinical question of relevance to health policy. Reduced
sample size and flexibility in the randomized arms included
are the main advantages of the method. However, it is only
applicable to cases where a well-conducted NMA is
available (or is possible to undertake) and the underlying
treatment effect under investigation is not expected to have
important variability across trial settings.
Efficient trial design is paramount to both public and
private funders of research: investing in a clinical trial
consumes funds that could instead be diverted to other
research activities. The proposed conditional trial design
has the potential to bring substantial benefits to
drug-licensing agencies and health technology assess-
ment (HTA) bodies. The approach depends on the avail-
ability of a coherent and fairly homogeneous network of
trials, relevant to the research question the future trial
aims to answer. Consequently, the feasibility and the
added benefit (in terms of reduction in sample size) of
the conditional trial design remain to be empirically
tested. User-friendly software to simplify the process will
be required and trialists will need to familiarize them-
selves with the technique. More importantly, wide adop-
tion of the conditional trial design will require a shift in
the current paradigm among regulators, reimbursement
decision bodies, and funders of research.
In recent years, drug-licensing agencies such as the
Food and Drug Administration (FDA) and European
Medicines Agency (EMA) have embraced conditional,
restricted approval mechanisms instead of making an
initial binary decision as to whether a new treatment
should be approved or rejected. Following initial market
entry, in many healthcare systems, HTA bodies are tasked
with advising practice guideline development panels and
payers about the therapeutic and economic value of
treatments. Similar to drug-licensing agencies, HTA
bodies increasingly require the generation of additional
evidence under so-called conditional coverage options
[19]. For example, the UK’s National Institute for Health
and Care Excellence can restrict the use of a new
treatment to research participants in its “only in research”
designation. In this capacity, drug-licensing agencies and
HTA bodies are well positioned to strengthen the link be-
tween existing and future research and ensure that design
features of future clinical trials are informed by the totality
of available relevant evidence. A research agenda of
national and international public and private funders of
trials which is streamlined with the evidence needs of
regulatory agencies, HTA bodies, and guideline developers
could benefit from the conditional planning of trials and
generate meaningful and relevant evidence faster and
more efficiently.
Conclusion
The role of NMA in guideline development, HTA [19],
and drug licensing [20] is increasingly recognized [21].
Conditional trial design extends the use of NMA to the
efficient design of future trials.
As Altman pointed out in 1994, we need less but better
research and research done for the right reasons [22].
Since then, specific recommendations have been made to
increase the value of clinical research and reduce waste
[23]. We believe that conditional trial design, used judi-
ciously based on a homogenous and coherent network of
the available controlled trials, can obtain conclusive re-
sults earlier, facilitate timely decision-making, and reduce
research waste.
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